WO2006072259A3 - Taurine synthesis, production and utility as a medicine - Google Patents

Taurine synthesis, production and utility as a medicine Download PDF

Info

Publication number
WO2006072259A3
WO2006072259A3 PCT/EG2005/000044 EG2005000044W WO2006072259A3 WO 2006072259 A3 WO2006072259 A3 WO 2006072259A3 EG 2005000044 W EG2005000044 W EG 2005000044W WO 2006072259 A3 WO2006072259 A3 WO 2006072259A3
Authority
WO
WIPO (PCT)
Prior art keywords
taurine
medicine
production
utility
bile salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EG2005/000044
Other languages
French (fr)
Other versions
WO2006072259A2 (en
Inventor
Magd Ahmed Kotb Abdalla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AP2007004084A priority Critical patent/AP2007004084A0/en
Priority to AU2005324199A priority patent/AU2005324199A1/en
Priority to EA200701434A priority patent/EA200701434A1/en
Priority to BRPI0519606-0A priority patent/BRPI0519606A2/en
Priority to EP05818935A priority patent/EP1844006A2/en
Priority to MX2007008196A priority patent/MX2007008196A/en
Priority to CA002593563A priority patent/CA2593563A1/en
Application filed by Individual filed Critical Individual
Priority to JP2007549796A priority patent/JP2008526789A/en
Publication of WO2006072259A2 publication Critical patent/WO2006072259A2/en
Priority to TNP2007000226A priority patent/TNSN07226A1/en
Priority to IL184221A priority patent/IL184221A0/en
Anticipated expiration legal-status Critical
Priority to NO20074937A priority patent/NO20074937A/en
Publication of WO2006072259A3 publication Critical patent/WO2006072259A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The quantitatively most important pathway for the excretion of cholesterol in mammals is the formation of bile salts (the conjugate bases of bile acids). The major bile salts are synthesized and secreted by as glycine or taurine conjugates. Taurine (2 aminoethyl sulphonic acid) is naturally produced by the liver cells and central nervous system cells, it is neuroprotective and is a cholesterol lowering agent with virtually no recorded side effects.
PCT/EG2005/000044 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine Ceased WO2006072259A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2007008196A MX2007008196A (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine.
AU2005324199A AU2005324199A1 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine
EA200701434A EA200701434A1 (en) 2005-01-05 2005-12-31 TAURINE SYNTHESIS, MANUFACTURE AND APPLICATION AS A MEDICINE
BRPI0519606-0A BRPI0519606A2 (en) 2005-01-05 2005-12-31 synthesis, production and utility of taurine as a remedy
EP05818935A EP1844006A2 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine
CA002593563A CA2593563A1 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine
JP2007549796A JP2008526789A (en) 2005-01-05 2005-12-31 Synthesis, production and use of taurine as medicine
AP2007004084A AP2007004084A0 (en) 2005-01-05 2005-12-31 Taurine synthesis production and utility as a medicine
TNP2007000226A TNSN07226A1 (en) 2005-01-05 2007-06-14 Taurine synthesis, production and utility as a medicine
IL184221A IL184221A0 (en) 2005-01-05 2007-06-26 Process for the manufacture of taurine
NO20074937A NO20074937A (en) 2005-01-05 2007-09-28 Taurine synthesis, production and use as a drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2005010013 2005-01-05
EG2005010013 2005-01-05

Publications (2)

Publication Number Publication Date
WO2006072259A2 WO2006072259A2 (en) 2006-07-13
WO2006072259A3 true WO2006072259A3 (en) 2007-10-04

Family

ID=36647837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2005/000044 Ceased WO2006072259A2 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine

Country Status (15)

Country Link
EP (1) EP1844006A2 (en)
JP (1) JP2008526789A (en)
KR (1) KR20070091198A (en)
CN (1) CN101146767A (en)
AP (1) AP2007004084A0 (en)
AU (1) AU2005324199A1 (en)
BR (1) BRPI0519606A2 (en)
CA (1) CA2593563A1 (en)
EA (1) EA200701434A1 (en)
IL (1) IL184221A0 (en)
MA (1) MA29238B1 (en)
MX (1) MX2007008196A (en)
NO (1) NO20074937A (en)
TN (1) TNSN07226A1 (en)
WO (1) WO2006072259A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130590T1 (en) 2007-11-30 2013-08-31 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
CN103382170B (en) * 2012-10-25 2015-04-08 潜江永安药业股份有限公司 Preparation method for taurine
CN106728405A (en) * 2016-11-15 2017-05-31 陈思文 A kind of taurine and water soluble tea polyphenol compound and preparation method and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565830A (en) * 1981-12-22 1986-01-21 Azuma Jun Ichi Method of ameliorating the subjective symptoms and objective signs in congestive heart failure
WO2001026642A2 (en) * 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
CN1340502A (en) * 2000-06-30 2002-03-20 张永春 Process for preparing taurine zinc
CN1587362A (en) * 2004-07-20 2005-03-02 刘辉 Taurine functional beer and its producing process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08208464A (en) * 1994-12-02 1996-08-13 Taisho Pharmaceut Co Ltd Treatment and prevention drug for hyperlipidemia
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
SE9601395D0 (en) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
NZ527924A (en) * 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565830A (en) * 1981-12-22 1986-01-21 Azuma Jun Ichi Method of ameliorating the subjective symptoms and objective signs in congestive heart failure
WO2001026642A2 (en) * 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
CN1340502A (en) * 2000-06-30 2002-03-20 张永春 Process for preparing taurine zinc
CN1587362A (en) * 2004-07-20 2005-03-02 刘辉 Taurine functional beer and its producing process

Also Published As

Publication number Publication date
CN101146767A (en) 2008-03-19
KR20070091198A (en) 2007-09-07
AP2007004084A0 (en) 2007-08-31
CA2593563A1 (en) 2006-07-13
EA200701434A1 (en) 2008-10-30
WO2006072259A2 (en) 2006-07-13
MX2007008196A (en) 2008-02-22
JP2008526789A (en) 2008-07-24
TNSN07226A1 (en) 2008-11-21
BRPI0519606A2 (en) 2009-02-25
NO20074937A (en) 2007-09-28
MA29238B1 (en) 2008-02-01
IL184221A0 (en) 2008-12-29
AU2005324199A1 (en) 2006-07-13
EP1844006A2 (en) 2007-10-17

Similar Documents

Publication Publication Date Title
UA93043C2 (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
EP3539380A3 (en) Improved cell composition and methods of making the same
WO2006010546A3 (en) Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
WO2009062118A3 (en) Modulation of protein trafficking
WO2008002573A3 (en) Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
WO2007106469A3 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2008006038A3 (en) Methods and compositions for butanol production
TNSN07226A1 (en) Taurine synthesis, production and utility as a medicine
EP3168299A3 (en) Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors
WO2009076602A8 (en) 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors
WO2008061671A3 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
ID25769A (en) FERMENTATION PROCESS FOR MAKING D-PANTOTENIC ACID USING STRAINS FROM FAMILI ENTEROBACTERIACEAE
WO2007134038A3 (en) Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
WO2008107471A3 (en) Modified hydroxypolymer conjugates with killing effect on tumor cells
WO2005123140A3 (en) Preparation of macromolecular conjugates by four-component condensation reaction
WO2007092847A3 (en) Solid phase synthesis of acridinium derivatives
WO2004110497A3 (en) Mitomycin conjugates cleavable by thiols
WO2005105154A8 (en) Polymer conjugate releasable under mild thiolytic conditions
WO2006091841A3 (en) Compositions and their uses directed to il-4r alpha
WO2006125531A3 (en) Thienopyridines
IL180311A0 (en) Process for the preparation of 4,4-difluoro-3-oxobutanoic acid esters
ID27240A (en) PROCESS FOR MAKING FERMENTATIVE D-PANTOTENIC ACID USING CORYNEFORM BACTERIA
WO2006089268A8 (en) Gene and cognate protein profiles and methods to determine connective tissue markers in normal and pathologic conditions
WO2007017510A3 (en) Isophthalic acid diamides for treating alzheimer&#39;s disease
WO2006105199A3 (en) Compositions and methods for synthesis of peptide and related conjugate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 556081

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 184221

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12007501399

Country of ref document: PH

Ref document number: 2593563

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005324199

Country of ref document: AU

WWE Wipo information: entry into national phase

Country of ref document: MX

Ref document number: MX/a/2007/008196

Ref document number: 2007549796

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580046066.3

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: DZP2007000441

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 1020077016443

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005324199

Country of ref document: AU

Date of ref document: 20051231

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005324199

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005818935

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 6017/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200701434

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2005818935

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0519606

Country of ref document: BR